FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1664517340> ?p ?o ?g. }

• W1664517340 endingPage "131" @default.
• W1664517340 startingPage "122" @default.
• W1664517340 abstract "Objectives The aim of the study was to test the antiviral efficacy of a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen, with potential beneficial metabolic effects, as maintenance therapy after induction with dual NRTIs and a boosted protease inhibitor (PI). Methods An open-label, noninferiority study was carried out. Antiretroviral therapy (ART)-naïve patients with CD4 count ≤ 350 cells/μL and HIV-1 RNA > 30 000 copies/mL (n = 207) were treated with zidovudine/lamivudine and lopinavir/ritonavir. After achieving HIV-1 RNA < 50 copies/mL on two consecutive occasions between weeks 12 and 24 after baseline, 120 patients (baseline: median HIV-1 RNA 5.19 log10 copies/mL; median CD4 count 180 cells/μL) were randomized to receive abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) (n = 61) or to continue the PI-based ART (n = 59). Results For the proportions of patients (intention-to-treat; missing = failure) with HIV-1 RNA < 400 copies/mL (PI group, 66%; ABC/3TC/ZDV group, 71%) and < 50 copies/mL (PI group, 63%; ABC/3TC/ZDV group, 62%) at 96 weeks, switching to ABC/3TC/ZDV was noninferior compared with continuing the PI regimen; the difference in failure rate (ABC/3TC/ZDV minus PI) was −4.4 percentage points [95% confidence interval (CI) −21.0 to +12.3 percentage points] and +0.4 percentage points (95% CI −16.9 to +17.7 percentage points), respectively. In the per protocol analysis, the difference in virological failure for HIV-1 RNA > 400 copies/mL (0 of 39 patients in the PI group and two of 45 patients in the NRTI group) and for HIV-1 RNA > 50 copies/mL (two of 39 and three of 45 patients, respectively) was +4.4 percentage points (95% CI −2.1 to +11.0 percentage points) and +1.5 percentage points (95% CI −8.6 to +11.7 percentage points), respectively, also showing noninferiority. Serum lipids significantly improved in the NRTI group, but not in the PI arm. Conclusions A single-class NRTI regimen after successful induction with standard ART had similar antiviral efficacy compared to continuation of a PI-based regimen at 96 weeks after baseline, with improved serum lipids." @default.
• W1664517340 created "2016-06-24" @default.
• W1664517340 creator A5001604373 @default.
• W1664517340 creator A5009261564 @default.
• W1664517340 creator A5011151244 @default.
• W1664517340 creator A5012696687 @default.
• W1664517340 creator A5013555986 @default.
• W1664517340 creator A5015698847 @default.
• W1664517340 creator A5016878897 @default.
• W1664517340 creator A5023093452 @default.
• W1664517340 creator A5030194581 @default.
• W1664517340 creator A5035223402 @default.
• W1664517340 creator A5044888668 @default.
• W1664517340 creator A5046961958 @default.
• W1664517340 creator A5069354463 @default.
• W1664517340 creator A5072308668 @default.
• W1664517340 creator A5075093239 @default.
• W1664517340 date "2014-12-04" @default.
• W1664517340 modified "2023-09-27" @default.
• W1664517340 title "A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study" @default.
• W1664517340 cites W1426208733 @default.
• W1664517340 cites W1488699347 @default.
• W1664517340 cites W1508213989 @default.
• W1664517340 cites W1606409921 @default.
• W1664517340 cites W1767400858 @default.
• W1664517340 cites W1971431164 @default.
• W1664517340 cites W2008989084 @default.
• W1664517340 cites W2013621260 @default.
• W1664517340 cites W2024720867 @default.
• W1664517340 cites W2039691644 @default.
• W1664517340 cites W2042632827 @default.
• W1664517340 cites W2048689803 @default.
• W1664517340 cites W2051347255 @default.
• W1664517340 cites W2055162315 @default.
• W1664517340 cites W2057394385 @default.
• W1664517340 cites W2075091799 @default.
• W1664517340 cites W2081568659 @default.
• W1664517340 cites W2092807708 @default.
• W1664517340 cites W2095704081 @default.
• W1664517340 cites W2103702352 @default.
• W1664517340 cites W2109118433 @default.
• W1664517340 cites W2116914456 @default.
• W1664517340 cites W2119433625 @default.
• W1664517340 cites W2124545045 @default.
• W1664517340 cites W2126311717 @default.
• W1664517340 cites W2145467751 @default.
• W1664517340 cites W2148750104 @default.
• W1664517340 cites W2152039537 @default.
• W1664517340 cites W2157645841 @default.
• W1664517340 cites W2161654186 @default.
• W1664517340 cites W2325916727 @default.
• W1664517340 cites W2328838076 @default.
• W1664517340 cites W2332910040 @default.
• W1664517340 cites W2335165509 @default.
• W1664517340 doi "https://doi.org/10.1111/hiv.12186" @default.
• W1664517340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25472825" @default.
• W1664517340 hasPublicationYear "2014" @default.
• W1664517340 type Work @default.
• W1664517340 sameAs 1664517340 @default.
• W1664517340 citedByCount "1" @default.
• W1664517340 countsByYear W16645173402015 @default.
• W1664517340 crossrefType "journal-article" @default.
• W1664517340 hasAuthorship W1664517340A5001604373 @default.
• W1664517340 hasAuthorship W1664517340A5009261564 @default.
• W1664517340 hasAuthorship W1664517340A5011151244 @default.
• W1664517340 hasAuthorship W1664517340A5012696687 @default.
• W1664517340 hasAuthorship W1664517340A5013555986 @default.
• W1664517340 hasAuthorship W1664517340A5015698847 @default.
• W1664517340 hasAuthorship W1664517340A5016878897 @default.
• W1664517340 hasAuthorship W1664517340A5023093452 @default.
• W1664517340 hasAuthorship W1664517340A5030194581 @default.
• W1664517340 hasAuthorship W1664517340A5035223402 @default.
• W1664517340 hasAuthorship W1664517340A5044888668 @default.
• W1664517340 hasAuthorship W1664517340A5046961958 @default.
• W1664517340 hasAuthorship W1664517340A5069354463 @default.
• W1664517340 hasAuthorship W1664517340A5072308668 @default.
• W1664517340 hasAuthorship W1664517340A5075093239 @default.
• W1664517340 hasConcept C126322002 @default.
• W1664517340 hasConcept C142462285 @default.
• W1664517340 hasConcept C159047783 @default.
• W1664517340 hasConcept C168563851 @default.
• W1664517340 hasConcept C2522874641 @default.
• W1664517340 hasConcept C2777869810 @default.
• W1664517340 hasConcept C2779465607 @default.
• W1664517340 hasConcept C2780216070 @default.
• W1664517340 hasConcept C2780593183 @default.
• W1664517340 hasConcept C2780727368 @default.
• W1664517340 hasConcept C2781413609 @default.
• W1664517340 hasConcept C3013748606 @default.
• W1664517340 hasConcept C71924100 @default.
• W1664517340 hasConcept C90924648 @default.
• W1664517340 hasConcept C98274493 @default.
• W1664517340 hasConceptScore W1664517340C126322002 @default.
• W1664517340 hasConceptScore W1664517340C142462285 @default.
• W1664517340 hasConceptScore W1664517340C159047783 @default.
• W1664517340 hasConceptScore W1664517340C168563851 @default.
• W1664517340 hasConceptScore W1664517340C2522874641 @default.
• W1664517340 hasConceptScore W1664517340C2777869810 @default.

• next